Utrogestan 300 mg Norge - norsk - Statens legemiddelverk

utrogestan 300 mg

besins healthcare ireland limited (1) - progesteron - vaginalkapsel, myk - 300 mg

Brukinsa Den europeiske union - norsk - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Tolvaptan Teva B.V. 30 mg / 90 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 30 mg / 90 mg

teva b.v. - tolvaptan - tablett - 30 mg / 90 mg

Tolvaptan Teva B.V. 30 mg / 60 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 30 mg / 60 mg

teva b.v. - tolvaptan - tablett - 30 mg / 60 mg

Tolvaptan Teva B.V. 45 mg / 15 mg Norge - norsk - Statens legemiddelverk

tolvaptan teva b.v. 45 mg / 15 mg

teva b.v. - tolvaptan - tablett - 45 mg / 15 mg

Tibsovo Den europeiske union - norsk - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Orserdu Den europeiske union - norsk - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - bryst neoplasms - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Medrol 16 mg Norge - norsk - Statens legemiddelverk

medrol 16 mg

orifarm as - metylprednisolon - tablett - 16 mg

Warfarin Orion 2.5 mg Norge - norsk - Statens legemiddelverk

warfarin orion 2.5 mg

orion corporation - espoo - warfarinnatrium - tablett - 2.5 mg

Rubraca Den europeiske union - norsk - EMA (European Medicines Agency)

rubraca

pharmaand gmbh - rucaparib camsylate - ovarie neoplasmer - antineoplastiske midler - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca er indisert som monoterapi for vedlikehold behandling av voksne pasienter med platinum-sensitive tilbakefall av høy klasse epithelial ovarian, egglederen, eller primær-peritoneal kreft som er i respons (hel eller delvis) til platinum-basert kjemoterapi.